Close Menu

Quest

Saying pooled testing for coronavirus was not for diagnostic purposes, Cigna had said it wouldn't reimburse for the method, but it plans to change its policy.

The companies said they will collaborate on driving operational improvements, creating price transparency, and improving consumer engagement and outcomes.

News items for the in vitro diagnostics industry for the week of August 3, 2020.

Lab firms are acquiring equipment and implementing approaches like pooled testing, but it remains unclear if this will be enough to meet a fall surge.

The company said the method will boost SARS-CoV-2 test capacity by 35,000 tests per day and bring turnaround times to one day for priority patients.

The inability to get COVID-19 test kits and the reagents to run the tests was especially problematic as 58 percent of labs cited such an issue.

The coming uptick in flu and other respiratory viruses will likely complicate the diagnosis of COVID-19 even as labs continue to struggle with capacity.

While Q2 revenues were down to $1.83 billion, the results represented a rebound from Q1 as the company saw expanded routine and SARS-CoV-2 testing.

Quest expects to deploy the pooled sample technique at its laboratories in Chantilly, Virginia and Marlborough, Massachusetts by the end of next week with additional laboratories to follow.

The assays are performed on nasal swab specimens self-collected by patients under the observation of a healthcare provider via telemedicine. 

Pages